Aadi Bioscience Management

Management criteria checks 2/4

Aadi Bioscience's CEO is Dave Lennon, appointed in Oct 2023, has a tenure of 1.08 years. total yearly compensation is $2.14M, comprised of 7.5% salary and 92.5% bonuses, including company stock and options. directly owns 0.093% of the company’s shares, worth €50.51K. The average tenure of the management team and the board of directors is 2.4 years and 3.3 years respectively.

Key information

Dave Lennon

Chief executive officer

US$2.1m

Total compensation

CEO salary percentage	7.5%
CEO tenure	1.1yrs
CEO ownership	0.09%
Management average tenure	2.4yrs
Board average tenure	3.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dave Lennon's remuneration changed compared to Aadi Bioscience's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$62m
Jun 30 2024	n/a	n/a	-US$65m
Mar 31 2024	n/a	n/a	-US$69m
Dec 31 2023	US$2m	US$160k	-US$66m

Compensation vs Market: Dave's total compensation ($USD2.14M) is above average for companies of similar size in the German market ($USD471.14K).

Compensation vs Earnings: Insufficient data to compare Dave's compensation with company performance.

CEO

Dave Lennon (53 yo)

1.1yrs

Tenure

US$2,135,687

Compensation

Mr. David J. Lennon, Ph.D. also known as Dave, is the Treasurer at Alliance for Regenerative Medicine from April, 2022. He is the CEO of Satellite Bio. He serves as President and CEO & Director at Aadi Bio...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Lennon	President	1.1yrs	US$2.14m	0.093% € 50.5k
Scott Giacobello	CFO, Treasurer	3yrs	US$1.97m	0% € 0
Stephen Rodin	Senior VP of Legal & General Counsel	2.8yrs	no data	no data
Raymond Steitz	Senior VP of Human Resources & Chief Human Resources Officer	2.4yrs	no data	no data
Bryan Ball	Chief Technical Operations Officer	2.3yrs	no data	0.41% € 220.9k

2.4yrs

Average Tenure

54yo

Average Age

Experienced Management: 3350's management team is considered experienced (2.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
David Lennon	President	1.1yrs	US$2.14m	0.093% € 50.5k
Caley Castelein	Independent Chairman of the Board	3.3yrs	US$258.91k	0.080% € 43.5k
Emma Reeve	Independent Director	3.2yrs	US$240.91k	0% € 0
Anupam Dalal	Independent Director	3.3yrs	US$235.91k	0.0046% € 2.5k
Karin Hehenberger	Independent Director	3.3yrs	US$227.41k	0% € 0
Richard Maroun	Independent Director	7.8yrs	US$240.91k	0% € 0
Mohammad Hirmand	Independent Director	1.7yrs	US$345.60k	0% € 0
Behzad Aghazadeh	Independent Director	3.3yrs	US$225.41k	0% € 0

3.3yrs

Average Tenure

53yo

Average Age

Experienced Board: 3350's board of directors are considered experienced (3.3 years average tenure).

Aadi Bioscience Management

Management criteria checks 2/4

Key information

Recent management updates

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Aadi Bioscience, Inc. Announces Executive Changes

High number of new directors

High number of new directors

High number of new directors

Aadi Bioscience, Inc. Announces Management Changes

Recent updates

Aadi Bioscience, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Aadi Bioscience, Inc. Approves Plan of Termination That Will Result in Workforce Reduction of 22 Employees, Representing Approximately 32% of the Workforce

Aadi Bioscience Provides PRECISION1 Trial Updates

Second quarter 2024 earnings released: US$0.54 loss per share (vs US$0.67 loss in 2Q 2023)

Aadi Bioscience, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Small Cap Comp Value Index

Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting

New minor risk - Profitability

Forecast to breakeven in 2026

First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023)

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings released: US$2.44 loss per share (vs US$2.69 loss in FY 2022)

Aadi Bioscience, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Aadi Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

Third quarter 2023 earnings released: US$0.60 loss per share (vs US$0.68 loss in 3Q 2022)

New minor risk - Market cap size

Aadi Bioscience, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$0.87 loss in 2Q 2022)

Aadi Bioscience, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: US$0.57 loss per share (vs US$0.66 loss in 1Q 2022)

High number of new directors

High number of new directors

High number of new directors

Aadi Bioscience, Inc. Announces Management Changes

High number of new directors

Third quarter 2022 earnings released: US$0.68 loss per share (vs US$9.17 loss in 3Q 2021)

Aadi Bioscience, Inc. Announces Executive Changes, Effective January 1, 2023

Aadi Bioscience, Inc. Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-Sirolimus at 34th EORTC-NCI-AACR Symposium

Now 21% undervalued

Second quarter 2022 earnings released: US$0.87 loss per share (vs US$0.22 loss in 2Q 2021)

Aadi Bioscience, Inc. Reports Impairment of Intangible Asset for the Second Quarter Ended June 30, 2022

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Microcap Value Index

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience, Inc. Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Present at 2022 ASCO Annual Meeting

High number of new directors

First quarter 2022 earnings released: US$0.66 loss per share (vs US$0.71 loss in 1Q 2021)

Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders

Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services

High number of new directors

Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Less than half of directors are independent

Aadi Bioscience, Inc. Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa

Interim Chief Financial Officer Lance Thibault has left the company

Aadi Bioscience, Inc. Announces FDA Approval of Its First Product Fyarro™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

No independent directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age